Drug intelligence / Profile preview

LAG3Pep

Development stage: Unknown
Lead developer: Kyungpook National University

Overview

LAG3Pep: sourced facts only. name: "These results show that LAG3Pep selectively binds to LAG-3 and has a potential as a LAG-3 blocker for cancer immunotherapy." [DOI:10.1158/1538-7445.am2022-599]; target: "These results show that LAG3Pep selectively binds to LAG-3 and has a potential as a LAG-3 blocker for cancer immunotherapy." [DOI:10.1158/1538-7445.am2022-599]; developer: "1Division of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu, Republic of Korea." [DOI:10.1158/1538-7445.am2022-599]

Targets

LAG3 (Lymphocyte activation Gene-3 protein)

Beyond the preview

Go deeper on LAG3Pep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAG3Pep.